| Literature DB >> 31797797 |
Enrico Franceschi1, Silvia Hofer2, Alba A Brandes1, Didier Frappaz3, Rolf-Dieter Kortmann4, Jacoline Bromberg5, Volodia Dangouloff-Ros6, Nathalie Boddaert6, Elke Hattingen7, Benedikt Wiestler8, Steven C Clifford9, Dominique Figarella-Branger10, Felice Giangaspero11, Christine Haberler12, Torsten Pietsch13, Kristian W Pajtler14, Stefan M Pfister14, Raphael Guzman15, Walter Stummer16, Stephanie E Combs17, Clemens Seidel4, Dagmar Beier18, Martin G McCabe19, Michael Grotzer20, Florence Laigle-Donadey21, Ana S Guerreiro Stücklin20, Ahmed Idbaih22, Matthias Preusser23, Martin van den Bent5, Michael Weller24, Peter Hau25.
Abstract
The European Association of Neuro-Oncology (EANO) and EUropean RAre CANcer (EURACAN) guideline provides recommendations for the diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma. The guideline is based on the 2016 WHO classification of tumours of the CNS and on scientific developments published since 1980. It aims to provide direction for diagnostic and management decisions, and for limiting unnecessary treatments and cost. In view of the scarcity of data in adults with medulloblastoma, we base our recommendations on adult data when possible, but also include recommendations derived from paediatric data if justified. Our recommendations are a resource for professionals involved in the management of post-pubertal and adult patients with medulloblastoma, for patients and caregivers, and for health-care providers in Europe. The implementation of this guideline requires multidisciplinary structures of care, and defined processes of diagnosis and treatment.Entities:
Mesh：
Year: 2019 PMID： 31797797 DOI： 10.1016/S1470-2045(19)30669-2
Source DB: PubMed Journal: Lancet Oncol ISSN： 1470-2045 Impact factor: 41.316